Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Promoting excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Fischer-Rasokat U, Assmus B, Seeger FH, Honold J, Leistner D, Fichtlscherer S, Schachinger J, Tonn T, Martin H, Dimmeler S, Zeiher AM. A Pilot Trial to Assess Potential Effects of Selective Intracoronary Bone Marrow–Derived Progenitor Cell Infusion in Patients With Nonischemic Dilated Cardiomyopathy. Final 1-Year Results of the Transplantation of Progenitor Cells and Functional Regeneration Enhancement Pilot Trial in Patients With Nonischemic Dilated Cardiomyopathy. Circ Heart Fail 2009;2:417-423.
Intracoronary infusion of BMC was applied in 33 patients with non-ischaemic dilated cardiomyopathy. After 3 months, regional wall motion of the target area and global left ventricular ejection fraction improved. After 12 months, serum NT-proBNP decreased, indicating an attenuation of left ventricular remodeling.
Recent experimental and clinical studies have demonstrated that either intracoronary or intramyocardial administration of bone marrow–derived progenitor cells (BMC) may contribute to increased neovascularization and stimulated angiogenesis in ischaemic tissue. The presented study provides premises that also patients with non-ischaemic may benefit from BMC administration, however precise mechanisms of these beneficial effects remain unclear.